Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results

Home/Newsroom/

Arrowhead Pharmaceuticals Reports...

Conference Call and Webcast Today at 4:30 p.m. EDT

PASADENA, Calif.–(BUSINESS WIRE)–May 8, 2018–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial
results for its fiscal 2018 second quarter ended March 31, 2018. The
company is hosting a conference call at 4:30 p.m. EDT to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm.
For analysts that wish to participate in the conference call, please
dial 855-215-6159 or 315-625-6887 and provide Conference ID 2895628.

A replay of the webcast will be available on the company’s website
approximately two hours after the conclusion of the call and will remain
available for 90 days. An audio replay will also be available
approximately two hours after the conclusion of the call and will be
available for 3 days. To access the audio replay, dial 855-859-2056 or
404-537-3406 and provide Conference ID 2895628.

Selected Fiscal 2018 Second Quarter and Recent Events

  • Strengthened the balance sheet with an equity financing yielding gross
    proceeds of $60.4 million
  • Received orphan drug designation from the United States Food and Drug
    Administration (FDA) for ARO-AAT, Arrowhead’s second-generation
    investigational medicine for the treatment of a rare genetic liver
    disease associated with alpha-1 antitrypsin deficiency
  • Initiated dosing in AROAAT1001 (NCT03362242),
    a Phase 1 single- and multiple-ascending dose study to evaluate the
    safety, tolerability, pharmacokinetics, and effect of ARO-AAT on serum
    alpha-1 antitrypsin levels in healthy adult volunteers
  • Initiated dosing in AROHBV1001 (NCT03365947),
    a Phase 1/2 study to evaluate the safety, tolerability, and
    pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in
    healthy adult volunteers, and to evaluate the safety, tolerability,
    and pharmacodynamic effects of multiple-ascending doses (MAD) of
    ARO-HBV in patients with chronic HBV
  • Presented clinical data on ARC-520, the company’s prior generation
    investigational medicine for the treatment of chronic hepatitis B
    infection, at The International Liver Congress™ 2018 (ILC), the annual
    meeting of the European Association for the Study of the Liver (EASL),
    including the following key results:

    • Multiple doses of ARC-520 resulted in s-antigen reductions in all
      patients by as much as 5.3 Log10
    • Where measurable, multi-log reductions were also seen in
      e-antigen, core-related antigen, DNA and HBV RNA
    • One e-antigen negative patient, while remaining on entecavir,
      serocleared for all measurable viral markers including s-antigen,
      core-related antigen, HBV RNA, and HBV DNA. We believe this will
      represent a functional cure
    • 2 out of 3 e-antigen positive and 2 out of 5 e-antigen negative
      patients, or half of the patients in the study, achieved
      productive and sustained host responses. These were characterized
      by mild ALT elevations coinciding with continued reductions in
      various viral markers which persisted after ARC-520 therapy was
      removed
    • Two patients that experienced sustained host responses but had not
      yet serocleared, appear poised to potentially seroclear if the
      trends in the decrease of viral markers continues
  • Presented preclinical data on both ARO-AAT and ARO-HBV at EASL
  • Made continued progress on the emerging pipeline of RNAi therapeutics
    developed using the Targeted RNAi Molecule (TRiMTM)
    platform including:

    • The cardiometabolic pipeline, which includes ARO-APOC3, targeting
      apolipoprotein C-III (ApoC3), and ARO-ANG3, targeting
      angiopoietin-like protein 3 (ANGPTL3)
    • The pulmonary pipeline, which includes ARO-ENaC, formerly called
      ARO-Lung1, which is an inhaled RNAi therapeutic targeting the
      epithelial sodium channel alpha subunit (αENaC) for the treatment
      of cystic fibrosis
    • ARO-HIF2 for the treatment of clear cell renal cell carcinoma

Selected Fiscal 2018 Second Quarter Financial Results

ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)
       
Three Months Ended

March 31,

 Six Months Ended

March 31,

OPERATING SUMMARY

 2018 2017 2018 2017
 
REVENUE $ 650,125 $ 8,985,930 $ 4,159,946 $ 13,351,426
OPERATING EXPENSES
Research and development 12,002,354 11,438,216 24,921,972 26,226,466
General and administrative expenses   3,681,830   3,677,356   8,085,381   8,156,491
TOTAL OPERATING EXPENSES   15,684,184   15,115,572   33,007,353   34,382,957
OPERATING LOSS (15,034,059 ) (6,129,642 ) (28,847,407 ) (21,031,531 )
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES   149,748   87,085   764,218   2,902,864
NET LOSS $ (14,884,311 ) $ (6,042,557 ) $ (28,083,189 ) $ (18,128,667 )
 
NET LOSS PER SHARE (BASIC AND DILUTED): $ (0.18 ) $ (0.08 ) $ (0.35 ) $ (0.25 )
WEIGHTED AVERAGE SHARES OUTSTANDING   84,083,937   74,629,855   79,406,838   73,019,726
 

FINANCIAL POSITION SUMMARY

 March 31, September 30,
2018 2017
CASH AND CASH EQUIVALENTS $ 69,805,117 $ 24,838,567
SHORT-TERM INVESTMENTS   21,736,820   40,769,539
TOTAL CASH RESOURCES (CASH AND INVESTMENTS)   91,541,937   65,608,106
OTHER ASSETS   35,456,978   38,414,174
TOTAL ASSETS   126,998,915   104,022,280
TOTAL LIABILITIES 13,283,833 23,155,118
TOTAL STOCKHOLDERS’ EQUITY   113,715,082   80,867,162
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 126,998,915 $ 104,022,280
 
SHARES OUTSTANDING 87,570,398 74,785,426
 

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform
Act:

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie,
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com